ANAB Historical PE Ratio Notes

— AnaptysBio (NASDAQ: ANAB) is a clinical-stage biotechnology company focused on developing innovative antibody-based therapeutics for unmet medical needs, primarily in inflammation, immunology, & oncology. The company discovers & develops monoclonal antibody candidates using its SHM-Platform—a proprietary technology that mimics somatic hypermutation, accelerating the natural process of antibody evolution. As of 2024, AnaptysBio's business model largely revolves around research & early-stage clinical development, with partnerships & licensing agreements supplementing its revenue stream until its therapeutics receive regulatory approval and commercialization. When analyzing ANAB's historical PE (price-to-earnings) ratio, it’s important to note that as a pre-commercial biotech, AnaptysBio often reports negative earnings or limited revenue, making its PE ratio either extremely high, volatile, or undefined (when earnings are negative) for extended periods. Thus, the company's PE ratio typically reflects investor sentiment about the potential value of its drug pipeline rather than current profitability. When reviewing historical price, earnings, and PE ratio data for ANAB, it is crucial to interpret these numbers in the context of clinical trial milestones, partnership announcements, or regulatory developments, which can cause sharp movements in valuations independent of current earnings.

On this page we presented the ANAB Historical PE Ratio information for AnaptysBio' stock. The average ANAB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 6.8. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ANAB historical PE based on this TTM earnings result method is 82.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ANAB historical PE result, against the recent PE: when this page was posted on 8/4/2026, the most recent closing price for ANAB had been 55.13, and the most recent quarterly earnings result, annualized, was 6.32. Meanwhile, the most recent TTM earnings summed to 0.28. From these numbers, we calculate the recent ANAB PE on 8/4/2026 based on annualized quarterly EPS was 8.7. Based on ANAB's history, that recent PE is elevated relative to the historical average, with the recent PE 27.9% higher than the historical average PE across our data set for AnaptysBio. Looking at the recent ANAB PE on 8/4/2026 based on TTM EPS, we calculate the ratio at 196.9. Based on ANAB's history, that recent PE is elevated relative to the historical average, with the recent PE 139.8% higher than the historical average PE across our AnaptysBio data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ANAB or any other given stock, valuation analysis for ANAB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate AnaptysBio PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ANAB. Thanks for visiting, and the next time you need to research ANAB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.